StockStory.org on MSN2h
Why Sarepta Therapeutics (SRPT) Stock Is Nosediving
Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 10.8% in the afternoon session after RBC analyst Brian ...
RBC downgrades Sarepta on ‘less bullish’ stance after doctor checks
RBC Capital analyst Brian Abrahams downgraded Sarepta (SRPT) to Sector Perform from Outperform with a price target of $87, down from $161. The ...
Sarepta downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital downgraded Sarepta (SRPT) to Sector Perform from Outperform with a price target of $87, down from $161.Don't Miss Our End of ...
Moderna Stock Sinks After Top FDA Official Resigns; Sarepta Gets Hit, Too.
Dr. Peter Marks led the FDA’s Center for Biologics Evaluation and Research. He was perhaps the agency’s best-known official.